Associated Genetic Biomarkers
NCI Definition: A glioblastoma that arises de novo. It is more commonly seen in older patients. Mutations in IDH1 or IDH2 genes are not present. 
Glioblastoma, IDH-wildtypes most frequently harbor alterations in TP53, PTEN, NF1, RB1, and CDKN2A .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, PTEN Mutation, and CDKN2A Loss are the most common alterations in glioblastoma, IDH-wildtype .
There are 6 clinical trials for glioblastoma, IDH-wildtype, of which 6 are open and 0 are completed or closed. Of the trials that contain glioblastoma, IDH-wildtype as an inclusion criterion, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open).
IDH2, MGMT, and TERT are the most frequent gene inclusion criteria for glioblastoma, IDH-wildtype clinical trials .
Incagn01876, vbi-1901, and bevacizumab are the most common interventions in glioblastoma, IDH-wildtype clinical trials.
Significant Genes in Glioblastoma, IDH-Wildtype
EGFR is altered in 14.71% of glioblastoma, IDH-wildtype patients .
EGFR is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, IDH-wildtype, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and glioblastoma, IDH-wildtype as inclusion criteria, 1 is phase 2 (1 open) .
TERT is altered in 1.96% of glioblastoma, IDH-wildtype patients .
TERT is an inclusion eligibility criterion in 2 clinical trials for glioblastoma, IDH-wildtype, of which 2 are open and 0 are closed. Of the trials that contain TERT status and glioblastoma, IDH-wildtype as inclusion criteria, 2 are phase 2 (2 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.